The DIA (Drug Information Association) has appointed Dr Holger Adelmann as its new senior vice president and managing director for DIA Europe, Middle East and Africa (EMEA).
Dr Adelmann brings nearly 30 years of clinical pharmacology experience to the role at the Washington, DC-headquartered group.
He joined the industry in 1989 and has previously held leading positions at AstraZeneca, Bayer, Merk Serono and Tropon.
Most recently, Dr Adelmann served as the global head of Merck Serono’s clinical pharmacology and clinical biomarker operations in Germany.
In that role he oversaw the reengineering of its clinical biomarker and companion diagnostics business to align with upcoming portfolio demands.
Barbara Lopez Kunz, DIA’s global chief executive, said: “Holger’s diverse background provides us with the leadership necessary to deliver that trusted, future-oriented knowledge and connect the global health care community to this rapidly evolving region.”
Dr Adlemann succeeds Dr Jytte Lynvig who retired from the post earlier this month.